Codexis is a privately held biosciences company applying proprietary synthetic chemistry technologies to create improved versions of small molecule therapeutics. Codexis’ technology enables novel process development solutions for efficient, cost-effective and environmentally friendly pharmaceutical manufacturing. Application of the company’s proprietary protein and strain engineering platform can also generate new intellectual property opportunities for pharmaceutical manufacturers, which may extend the drug product lifecycle. Codexis has more than 15 strategic alliances, and the company’s technology is being applied to the development of more than 20 therapeutic products worldwide. Codexis, Inc. began operations as an independent company in 2002.

Recent Milestones
edit

Went public with stock symbol CDXS. (4/21/10)

Posted 7/2/10 at 12:22pm
Codexis received $37M in Series D funding. (8/14/06)

Posted 4/20/10 at 4:01am via codexis.com
Codexis added Peter Strumph as Interim CEO.

Posted 3/12/12 at 9:05pm
Codexis added David Anton as CTO & SVP, Process Development and Manufacturing.

Posted 3/12/12 at 9:05pm
Codexis added Brian Dowd as Interim CFO.

Posted 3/12/12 at 9:05pm